Definitive Contract HHSN261201400020C

This is a federal contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Asuragen Incorporated, a small business. The contract is for the development and supply of a BCR-ABL 1 RT-QPCR test to improve monitoring of chronic myeloid leukemia (CML). This is a Phase II Small Business Innovation Research (SBIR) contract with a ceiling value of $1,489,494.00. The contract is a definitive contract with a cost-plus-fixed-fee pricing...

Advanced Cell Diagnostics, Inc. (ACD) has been awarded a firm fixed price purchase order valued at fifteen thousand and forty dollars ($15,040) from the National Institutes of Health's National Institute of Dental and Craniofacial Research. The contract is for ACD to provide its proprietary RNAScope MFV2 in-house assay project service fee and accompanying reagent kits and control/marker probe costs. ACD will deliver the requested products and services in support of molecular pathology research...

This is a $1,994,911 firm fixed price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Earlydiagnostics Inc., doing business as Earlydx. The contract is part of the NCI's Small Business Innovation Research (SBIR) program and has a total small business set-aside designation. The contract supports Earlydx's research and development of a cloud-based liquid-biopsy platform for the Cancer Research Data Commons. Earlydx is a for-profit...

This contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Mdxhealth, Inc., a for-profit organization, to provide proprietary genetic testing services in support of patient diagnosis, such as for cancer. The contract is a Blanket Purchase Agreement (BPA) Call under the VA's existing Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II). The contract has a potential value of $232,732.75 and a completion date of...

Advanced Cell Diagnostics, Inc. (ACD) has been awarded a $26,945 firm fixed price purchase order by the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NIH NINDS) to provide RNAScope HiPlex Probes and Reagents. The solicitation sought these specific products from ACD to support research at NIH NINDS aimed at identifying and quantifying 40 RNA molecules in mouse brain tissue using ACD's proprietary RNAScope assay method. Delivery within one week of order...

This is a definitive contract awarded by the National Cancer Institute, a civilian agency of the U.S. government, to Cellerant Therapeutics, Inc. for the development of IL1RAP antibodies targeting acute myeloid leukemia (AML) cancer stem cells. The contract has a firm fixed price of $223,524.00 and a completion date of August 11, 2015. This contract is not designated as a set-aside. The purpose of the contract is to support the development of these antibodies, which may contribute to the...

This contract, awarded by the National Institutes of Health (NIH) Clinical Center to CareDx Lab Solutions Inc., provides ALLOSEQ TX17 KITS, FREIGHT, DRY ICE AND GEL PACKS for the NIH's Department of Transfusion Medicine. The $77,500.00 firm fixed-price purchase order has a period of performance from August 1, 2021 to July 31, 2022. CareDx Lab Solutions Inc. is a subsidiary of the parent company CareDx, Inc., a for-profit organization specializing in advanced medical testing products and services...

Earlydiagnostics Inc., doing business as Earlydx, was awarded a $395,918 firm fixed price contract by the National Institutes of Health National Cancer Institute under the Small Business Innovation Research program. The contract has a total small business set aside designation. Earlydx will provide cloud-based development of a liquid-biopsy platform for the Cancer Research Data Commons, as requested in Topic 428 of the NIH/CDC SBIR solicitation seeking proposals for next generation...

Archerdx LLC, a subsidiary of Invitae Corporation, has been awarded a firm fixed price purchase order by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Under this contract, Archerdx will provide the NHLBI with custom DNA sequencing library reagents to detect and quantify the frequency of acute myeloid leukemia-associated mutations in patient samples. The contract has a period of performance from September 12, 2023 through November 11, 2023...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Champions Oncology, Inc. The $1,999,931.00 Firm Fixed Price contract is for the development of CDX (circulating tumor cell-derived xenograft) models to address the slow growth rate of prostate patient-derived xenografts (PDXs). The period of performance is from September 19, 2017 to September 18, 2019, with an ultimate completion date of March 18,...